From the unlocking of pension benefits in Nova Scotia to new pay transparency rules in Ontario, stories about pension and employment legislation caught the eyes of Benefits Canada’s readers in 2024. In addition, a pair of articles on the rollout of new glucagon-like peptide-1 receptor agonist medications in Canada were also popular with readers. Here […]
Between 2019 and 2023, chronic disease drug claims increased much faster among younger plan members compared to older generations, according to a new report by Sun Life. The report, which analyzed drug claims data of more than 3 million plan members over a five-year period, found across all age groups, nearly half (45.1 per cent) of […]
Treating obesity with all available evidence-based tools ultimately costs less than not treating it, according to panellists during a webinar hosted by Benefits Canada and sponsored by Eli Lilly Canada Inc. in collaboration with Obesity Canada. Dr. Akshay Jain (pictured right), a clinical and research endocrinologist, provided an overview of obesity — a chronic, progressive, […]
An article on employees’ views of employer-sponsored benefits plans was the most-read story on BenefitsCanada.com this past week. Here are the top five human resources, benefits, pension and investment stories of the last week: 1. Survey finds seven in 10 Canadian workers dissatisfied with their employer’s benefits plan 2. Claims for obesity, diabetes medications up in 2023: […]
The percentage of claimants filing claims for obesity drugs increased by 43 per cent in 2023, according to a new report by GreenShield. The report, which analyzed the insurer’s 2023 claims data, found diabetes medications saw a 13 per cent increase in cost, accounting for nine per cent of total drug costs in 2023. There […]
With lyrics adapted to the tune of ‘Magic’ by Scottish pop group Pilot, the melody of ‘Oh, Oh, Oh, Ozempic’ is splashed across U.S. televisions in a snappy advertising campaign. The commercial push is likely unnecessary. Ozempic, one of the brand names of a glucagon-like peptide-1 receptor agonist medication used to treat type 2 diabetes, […]
U.S. employers’ health benefits costs are expected to increase to nearly eight per cent for 2025, the highest amount in more than a decade, according to a new survey by Business Group on Health. The survey, which polled 125 large employers, found they’re planning to continue to absorb much of the increases at least for […]
With obesity now understood to be a chronic health condition, it’s time for plan sponsors to revisit their approach to weight loss medications, said Philippe Laplante, principal for pension and benefits at Eckler Ltd., during a session at Benefits Canada’s 2024 Vancouver Benefits Summit in May. The conversation about extending coverage to new, high-cost anti-obesity […]
Roughly a third (34 per cent) of employers in the U.S. are providing coverage for glucagon-like peptide-1 medications for both diabetes care and weight-loss management in 2024, up from 26 per cent in 2023, according to a new survey by the International Foundation of Employee Benefit Plans. However, the survey, which polled more than 270 U.S. employers, found more […]
An article detailing a stark increase in the use of obesity medications among Canadian employer-sponsored benefits plan members was the most-read article on BenefitsCanada.com this week. Here are the top five human resources, benefits, pension and investment stories of the past week: 1. Claims for obesity drugs increased 42% in 2023, 92% since 2020: report 2. How […]